B
BioVersys
Biotech & Life Sciences · Basel, Switzerland · Founded 2010
Privately held Swiss biopharmaceutical company MoreLess
BioVersys is a Swiss pharmaceutical company based in Basel, specializing in the research and development of small molecules targeting antimicrobial resistance (AMR). The company focuses on creating therapies that address bacterial infections through novel modes of action and targets. BioVersys operates in the pharmaceutical and biotech sectors, serving healthcare systems globally by providing solutions to combat the silent pandemic of AMR. The business model revolves around advancing clinical trials and bringing effective treatments to market, thereby generating revenue through the commercialization of its pharmaceutical products. The company is governed by a board of directors with extensive experience in the pharma and biotech industries, ensuring strategic oversight and guidance. BioVersys is committed to improving patient outcomes and safeguarding global health by addressing one of the most pressing medical threats of our time. Keywords: antimicrobial resistance, small molecules, bacterial infections, pharmaceutical, biotech, clinical trials, healthcare, global health, therapies, Basel
Talent graph
BioVersys's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on BioVersys's cap table
Sourced from Dealroom's funding history.







Global footprint
Where BioVersys has talent and traffic
team presence
Market sentiment
What the market is saying about BioVersys
An AI-synthesized read of the highest-engagement posts about BioVersys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioVersys on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.